EDITORIAL article
Front. Oncol.
Sec. Breast Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1664563
This article is part of the Research TopicAdvances in Tumor Microenvironment, Immunology and Immunotherapy of Breast CancerView all 11 articles
Editorial: Advances in Tumor Microenvironment, Immunology and Immunotherapy of Breast Cancer
Provisionally accepted
- 1Department of Breast Surgery, Breast Disease Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
- 2Institute of Precision Medicine, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
- 3Department of Breast Surgery, Kyoto University Hospital, Kyoto, Japan
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
TME complexity significantly impacts disease characteristics and treatment efficacy. Xu et al. performed a comprehensive bibliometric analysis using Bibliometrix (R) and VOSviewer to map the 27-year evolution of triple-negative breast cancer (TNBC) clinical trials research globally. Their analysis highlights the groundbreaking advances in immunotherapy for TNBC treatment alongside the growing importance of antibody-drug conjugates (ADCs) in targeted therapy approaches. Wang et al. comprehensively reviewed the existing research on the resistance mechanisms of trastuzumab for human epidermal growth factor 2 (HER2+) breast cancer. One aspect in this review particularly emphasizes TME-mediated resistance pathways operating through both cell-autonomous and noncell-autonomous mechanisms, including impaired antibody-dependent cellular cytotoxicity (ADCC), aberrant secretion of immunosuppressive cytokines, stromal remodeling, and altered immune cell infiltration.Hypoxia is a significant feature of TME heterogeneity that arises from dysregulated tumor 37 vasculature heightened metabolic demand.
Keywords: Tumor Microenvironment, immunology, Immunotherapy, breast cancer, Drug Resistance
Received: 12 Jul 2025; Accepted: 26 Aug 2025.
Copyright: © 2025 Zhang, Cui, Zheng, Kawaguchi and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Kosuke Kawaguchi, Department of Breast Surgery, Kyoto University Hospital, Kyoto, Japan
Ying Lin, Department of Breast Surgery, Breast Disease Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.